Comparing the effects of three different erythropoiesis stimulating agent [Erythropoietin, Methoxy polyethylene glycol-epoetin beta and Darbepoetin alpha] on wound healing

2017 ◽  
Author(s):  
Bircan Kolbaşı
Keyword(s):  
Wound Healing ◽  
Polyethylene Glycol ◽  
Epoetin Beta ◽  
Darbepoetin Alpha ◽  
Methoxy Polyethylene Glycol

Pharmacokinetic and Pharmacodynamic Properties of Methoxy Polyethylene Glycol-Epoetin Beta Are Unaffected by the Site of Subcutaneous Administration1

2007 ◽  
Vol 47 (11) ◽  
pp. 1390-1397 ◽  
Author(s):  
Steven Fishbane ◽  
Anne Pannier ◽  
Xavier Liogier ◽  
Paul Jordan ◽  
Frank C. Dougherty ◽  
...  
Keyword(s):  
Polyethylene Glycol ◽  
Epoetin Beta ◽  
Methoxy Polyethylene Glycol

scholarly journals Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD

2019 ◽  
Vol 14 (12) ◽  
pp. 1701-1710 ◽  
Author(s):  
Francesco Locatelli ◽  
Thierry Hannedouche ◽  
Steven Fishbane ◽  
Zoe Morgan ◽  
Delphine Oguey ◽  
...  
Keyword(s):  
Polyethylene Glycol ◽  
Major Adverse Cardiovascular Events ◽  
Primary Analysis ◽  
Open Label ◽  
Erythropoiesis Stimulating Agents ◽  
Link Type ◽  
Epoetin Beta ◽  
End Point ◽  
All Cause Mortality ◽  
Methoxy Polyethylene Glycol

Background and objectivesErythropoiesis-stimulating agents correct anemia of CKD but may increase cardiovascular risk. We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta with those of the shorter-acting agents epoetin alfa/beta and darbepoetin alfa in patients with anemia of CKD.Design, setting, participants, & measurementsWe conducted a multicenter, open-label, noninferiority trial in which patients were randomized to receive methoxy polyethylene glycol-epoetin beta or reference erythropoiesis-stimulating agents, stratified by maintenance or correction treatment status and C-reactive protein level. The trial had a prespecified noninferiority margin of 1.20 for the hazard ratio (HR) for the primary end point (a composite of all-cause mortality, nonfatal myocardial infarction or stroke, adjudicated by an independent blinded committee). This trial is registered with ClinicalTrials.gov, number NCT00773513.ResultsIn total, 2818 patients underwent randomization, received methoxy polyethylene glycol-epoetin beta or a reference agent, and were followed for a median of 3.4 years (maximum, 8.4 years). In the modified intention-to-treat analysis, a primary end point event occurred in 640 (45.4%) patients in the methoxy polyethylene glycol-epoetin beta arm, and 644 (45.7%) in the reference arm (HR 1.03; 95% confidence interval [95% CI], 0.93 to 1.15, P=0.004 for noninferiority). All-cause mortality was not different between treatment groups (HR 1.06; 95% CI, 0.94 to 1.19). Results in patient subgroups on dialysis or treated in the correction or maintenance settings were comparable to the primary analysis.ConclusionsIn patients with anemia of CKD, once-monthly methoxy polyethylene glycol-epoetin beta was noninferior to conventional, shorter-acting erythropoiesis-stimulating agents with respect to rates of major adverse cardiovascular events or all-cause mortality.

Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients

Nephrology ◽  
2013 ◽  
Vol 18 (8) ◽  
pp. 533-538 ◽  
Author(s):  
Bo Ying Choy ◽  
Man Fai Lam ◽  
Terence Yip ◽  
Hon Lok Tang ◽  
Ping Nam Wong ◽  
...  
Keyword(s):  
Polyethylene Glycol ◽  
Dosing Regimen ◽  
Dialysis Patients ◽  
Epoetin Beta ◽  
Methoxy Polyethylene Glycol
Sign in / Sign up

Export Citation Format

Share Document